HEALTH● LOWAug 14 · Aug 14, 2026, 5:28 AM
Kyntra Bio targets FG-3246 median rPFS of 10 months or greater as it plans roxadustat Phase III start in Q4 2026
Seeking Alpha Tech
Kyntra Bio aims for a median rPFS of 10 months or more for FG-3246 and plans to begin a Phase III trial for roxadustat in Q4 2026. This indicates developments in the company's drug pipeline and clinical trial schedule.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH42m agoUganda says it has no active Ebola cases, but infections in Kenya and Nigeria are prompting fresh scrutinyDW News [en]HEALTH50m agoAfrica CDC probes possible link between Ebola cases in Nigeria, KenyaPremium TimesHEALTH51m agoRobert Waldinger, Harvard psychiatrist expert in longevity and well-being: "People in their 80s reflected on their lives, they were asked what they were most proud of, it was never an award won or money accumulated, but their connections with other people"ClarínHEALTH1h agoEbola: Nigerian govt urges 15 states to speed up preparednessPremium Times